Lv7
3820 积分 2021-05-25 加入
Wrestling with the RAS cancer drug pipeline
10天前
已完结
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D
23天前
已完结
Updated patent review for Hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present)
1个月前
已完结
Next steps for targeted protein degradation
3个月前
已完结
Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
4个月前
已完结
RAS Drug Discovery Past, Present and Future
4个月前
已完结
The emergence of pan-KRAS drugs
4个月前
已完结
The emergence of pan-KRAS drugs
4个月前
已关闭
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity
4个月前
已完结
Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
4个月前
已完结
Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology
皖公网安备34019202002308
